Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Joyce

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
ACS Applied Materials & Interfaces|January 19, 2022
Liquid Polymer/Metallic Salt-Based Stretchable Strain Sensor to Evaluate Fruit GrowthHyun Jae Lee, Robin Joyce, Junghoon Lee
Cancer Biotherapy & Radiopharmaceuticals|May 19, 2006
Extravazation of therapeutic yttrium-90-ibritumomab tiuxetan (zevalin): a case reportGethin Williams, Matthew R Palmer, J Anthony Parker, et al.
Angiology|October 3, 2008
Significance of close surveillance of patients with peripheral arterial diseaseRobin Joyce Barrows, Ulrike Krumsdorf, Alexandra Zankl, et al.
Abdominal Imaging|January 21, 2014
Pancreatic atrophy in patients with chronic graft-versus-host diseaseOlga Rachel Brook, Charles P Mullan, Mishal Mendiratta-Lala, et al.
Blood Advances|May 23, 2020
Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trialJeffrey I Zwicker, Joanna Roopkumar, Maneka Puligandla, et al.
Clinical Lymphoma|September 30, 2004
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphomaLeo I Gordon, Thomas Witzig, Arturo Molina, et al.
British Journal of Haematology|July 27, 2022
Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapyMatt Weinstock, Pavania Elavalakanar, Susan Bright, et al.
American Journal of Hematology|August 19, 2014
Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantationVincent T Ho, Haesook T Kim, Grace Kao, et al.
The Lancet. Haematology|October 11, 2021
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 studySarah C Rutherford, Jeremy S Abramson, Nancy L Bartlett, et al.
Blood|June 13, 2019
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphomaJeremy S Abramson, Jon E Arnason, Ann S LaCasce, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
ACS Applied Materials & Interfaces|January 19, 2022
Liquid Polymer/Metallic Salt-Based Stretchable Strain Sensor to Evaluate Fruit GrowthHyun Jae Lee, Robin Joyce, Junghoon Lee
Cancer Biotherapy & Radiopharmaceuticals|May 19, 2006
Extravazation of therapeutic yttrium-90-ibritumomab tiuxetan (zevalin): a case reportGethin Williams, Matthew R Palmer, J Anthony Parker, et al.
Angiology|October 3, 2008
Significance of close surveillance of patients with peripheral arterial diseaseRobin Joyce Barrows, Ulrike Krumsdorf, Alexandra Zankl, et al.
Abdominal Imaging|January 21, 2014
Pancreatic atrophy in patients with chronic graft-versus-host diseaseOlga Rachel Brook, Charles P Mullan, Mishal Mendiratta-Lala, et al.
Blood Advances|May 23, 2020
Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trialJeffrey I Zwicker, Joanna Roopkumar, Maneka Puligandla, et al.
Clinical Lymphoma|September 30, 2004
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphomaLeo I Gordon, Thomas Witzig, Arturo Molina, et al.
British Journal of Haematology|July 27, 2022
Complete responses to odronextamab in two patients with diffuse large B-cell lymphoma refractory to chimeric antigen receptor T-cell therapyMatt Weinstock, Pavania Elavalakanar, Susan Bright, et al.
American Journal of Hematology|August 19, 2014
Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantationVincent T Ho, Haesook T Kim, Grace Kao, et al.
The Lancet. Haematology|October 11, 2021
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 studySarah C Rutherford, Jeremy S Abramson, Nancy L Bartlett, et al.
Blood|June 13, 2019
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphomaJeremy S Abramson, Jon E Arnason, Ann S LaCasce, et al.
Pageof 4